Furthermore, HER2 phosphorylation promotes cell proliferation via the RAS-ERK pathway and inhibits cell death via the PI3K-AKT-mTOR pathway, which makes the phosphorylated HER2 a marker of poor prognosis [15] and a useful molecular target in breast cancer therapy. This evidence concerns the gene ERBB2 and breast cancer.